Continuous exposure to low-dose cisplatin and apoptosis

被引:14
作者
Kishimoto, S [1 ]
Kawazoe, Y [1 ]
Ikeno, M [1 ]
Fukushima, S [1 ]
Takeuchi, Y [1 ]
机构
[1] Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Kobe, Hyogo 6512180, Japan
关键词
apoptosis; low-dose; cisplatin (CDDP);
D O I
10.1248/bpb.28.1954
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A high concentration of cisplatin induces apoptosis in many tumor cell lines. Whether cisplatin induces apoptosis even in a controlled release formulation has not been determined. We therefore studied the relationship between the dosing regimen of cisplatin and the induction of apoptosis in rat hepatoma AH-109A cells. A colorimetric assay was used to quantify cell proliferation and viability, and caspase activity was determined using an exogenous fluorogenic peptide substrate. When delivered as a single dose, cisplatin caused a dose-dependent inhibition of AH-109A growth and enhancement of caspase-3 activity. Also, DNA laddering was detected in cells that had elevated caspase-3 activity. However, caspase-3 activity was low and DNA laddering and a sub-G1 population were not detected when cells were treated with a combination of cisplatin and the caspase inhibitor Z-VAD-FMK. These results suggest that cisplatin is cytotoxic in AH-109A cells because it induces apoptosis. We next examined intermittent exposure to cisplatin to estimate the effects of continuous exposure by a controlled release formulation. Cisplatin was divided into equal parts and was added intermittently into the medium resulting in the same final concentration as the single dose. The individual additions alone were not cytotoxic, but all of the doses together had a similar cytotoxic effect as a single exposure of cisplatin. The intermittent exposure resulted caspase-3 activity even higher than a single dose. These findings indicate that cisplatin induces apoptosis in AH-109A cells when delivered continuously even at the concentration that alone have no activity.
引用
收藏
页码:1954 / 1957
页数:4
相关论文
共 26 条
[1]   PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in Vivo drug residence in blood properties [J].
Avgoustakis, K ;
Beletsi, A ;
Panagi, Z ;
Klepetsanis, P ;
Karydas, AG ;
Ithakissios, DS .
JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) :123-135
[2]  
EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275
[3]  
EVANS DL, 1994, CANCER RES, V54, P1596
[4]   Is cisplatin-induced cell death always produced by apoptosis? [J].
Gonzalez, VM ;
Fuertes, MA ;
Alonso, C ;
Perez, JM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :657-663
[5]   Structure, recognition, and processing of cisplatin-DNA adducts [J].
Jamieson, ER ;
Lippard, SJ .
CHEMICAL REVIEWS, 1999, 99 (09) :2467-2498
[6]  
JOHNSON SW, 1994, CANCER RES, V54, P5911
[7]   Molecular mechanisms involved in cisplatin cytotoxicity [J].
Jordan, P ;
Carmo-Fonseca, M .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (8-9) :1229-1235
[8]  
Kishimoto S, 2000, BIOL PHARM BULL, V23, P637
[9]  
Kishimoto S, 2000, BIOL PHARM BULL, V23, P487
[10]   In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis(myristato)] platinum (II) suspended in lipiodol [J].
Kishimoto, S ;
Miyazawa, K ;
Fukushima, S ;
Takeuchi, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (01) :99-104